Maria Isabel B. L. B.
- Country
- Spain
- Department
- Oncology
Research Overview
- Palazestrant and Ribociclib versus Letrozole and Ribociclib for First-line Treatment of ER+/HER2- Advanced Breast Cancer
- Efficacy and Safety of Inavolisib plus Combination Therapy in Patients with Endocrine-Resistant HR+/HER2- Advanced Breast Cancer with Chromosome 8p Loss
- Comparison of RO7771950 plus combination therapy versus tucatinib plus combination therapy in pretreated HER2-positive locally advanced or metastatic breast cancer
Data & Insights
Has run more than one trial at 513 of 856 partner sites.
Specializations
HER2-Positive Breast Cancer
The investigator specializes in treating HER2-positive breast cancer across various stages, with particular focus on early-stage disease and metastatic conditions. Their research encompasses innovative therapeutic approaches using targeted treatments.
- Early-stage HER2-positive breast cancer management
- Advanced and metastatic HER2-positive disease
- Combination therapy approaches
Expertise extends to developing treatment strategies for patients with brain metastases and locally advanced disease.
Hormone Receptor-Positive Disease
The investigator focuses on treating hormone receptor-positive breast cancer, particularly exploring novel therapeutic combinations and treatment strategies for endocrine-resistant disease.
- ESR1-mutated breast cancer
- Advanced hormone-positive disease
- Endocrine therapy resistance
Special interest in developing treatments for patients with PIK3CA mutations and managing treatment-related complications.
Precision Medicine Approaches
The investigator develops personalized treatment strategies based on specific molecular markers and genetic mutations in breast cancer.
- Biomarker-driven therapy selection
- Targeted therapeutic approaches
- Treatment resistance mechanisms
Expertise in implementing circulating tumor DNA analysis for treatment monitoring and decision-making.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.